Federal officials continue to make operational adjustments in the health law marketplaces and meet with some insurers to encourage them to offer more plans in areas of the country that are forecast to be low on competition following the withdrawal of some major insurers for 2017, Department of Health and Human Services Secretary Sylvia Burwell said Thursday.

The CMS' plan to eliminate Medicare payments for new off-campus outpatient departments has kicked up fierce opposition from hospitals. As the comment period comes to a close, hospitals argue it threatens not just lost revenue but also substantial and unavoidable legal risks.

Cal INDEX, a highly touted database of patient medical records backed by two of California’s largest health insurers, is searching for a new chief executive as it tries to overcome a slow start.

Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said Monday it will offer a generic version of the life-saving allergy treatment.

At least eight pharmaceutical companies sell a decades-old drug that treats gallstones, but the competition has done little to keep its price down.

State Sen. Ed Hernandez's attempt to push through a drug pricing transparency bill sputtered this year, but the West Covina Democrat still wants his colleagues to weigh in on the latest controversy in the cost of prescription drugs: the surging price of EpiPens.